CleftGeneDB-Search

Gene: ANP32B

Basic information

Tag	Content
Uniprot ID	Q92688; B2R9C7; O00655; P78458; P78459;
Entrez ID	10541
Genbank protein ID	CAA68855.1; EAW58865.1; BAG36474.1; AAH13003.1; CAA69265.1; AAB37579.1; CAA68856.1; AAH19658.1;
Genbank nucleotide ID	NM_006401.2
Ensembl protein ID	ENSP00000345848
Ensembl nucleotide ID	ENSG00000136938
Gene name	Acidic leucine-rich nuclear phosphoprotein 32 family member B
Gene symbol	ANP32B
Organism	Homo sapiens
NCBI taxa ID	9606
Cleft type
Developmental stage
Data sources	Homology search
Reference
Functional description	Multifunctional protein working as a cell cycle progression factor as well as a cell survival factor. Required for the progression from the G1 to the S phase. Anti-apoptotic protein which functions as a caspase-3 inhibitor. Has no phosphatase 2A (PP2A) inhibitor activity (By similarity). Exhibits histone chaperone properties, stimulating core histones to assemble into a nucleosome.
Sequence	MDMKRRIHLE LRNRTPAAVR ELVLDNCKSN DGKIEGLTAE FVNLEFLSLI NVGLISVSNL 60 PKLPKLKKLE LSENRIFGGL DMLAEKLPNL THLNLSGNKL KDISTLEPLK KLECLKSLDL 120 FNCEVTNLND YRESVFKLLP QLTYLDGYDR EDQEAPDSDA EVDGVDEEEE DEEGEDEEDE 180 DDEDGEEEEF DEEDDEDEDV EGDEDDDEVS EEEEEFGLDE EDEDEDEDEE EEEGGKGEKR 240 KRETDDEGED D 251

Abbreviation :
CLO : cleft lip only. CPO : cleft palate only. CLP : cleft lip and palate. CL/P : cleft lip with/without cleft palate.
For humans: CL/P, CLO, CPO, and CLP. For mice: CLO, CLP, and CPO.

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

PDB ID
2ELL
2RR6
2ELL

Protein disorder information

Orthologous information

Relation	Gene symbol	Entrez ID	UniProt ID	Cleft type	Species	Evidence	Details
1:1 ortholog	ANP32B		A0A452EQC6		Capra hircus	Prediction	More>>
1:1 ortholog	ANP32B	10541	Q92688		Homo sapiens	Prediction	More>>
1:1 ortholog	Anp32b	67628	Q9EST5	CPO	Mus musculus	Publication	More>>
1:1 ortholog	ANP32B	464605	H2QXJ7		Pan troglodytes	Prediction	More>>
1:1 ortholog	Anp32b		F1LP34		Rattus norvegicus	Prediction	More>>
1:1 ortholog	anp32b	322000	F1Q4N7		Danio rerio	Prediction	More>>

Other genetic variants/mutations

ID	Variant	Type	Disease	Chromosome\Coordinate	Evidence
NCI-TCGA novel	p.Asp2Asn	missense variant	-	NC_000009.12:g.97983559G>A	NCI-TCGA
rs1277307714	p.Met3Val	missense variant	-	NC_000009.12:g.97983562A>G	gnomAD
rs1440265144	p.Lys4Asn	missense variant	-	NC_000009.12:g.97983567G>C	TOPMed,gnomAD
rs1211785897	p.Arg5Trp	missense variant	-	NC_000009.12:g.97983568A>T	gnomAD
rs1246417199	p.Arg6Lys	missense variant	-	NC_000009.12:g.97983572G>A	TOPMed
rs1237744954	p.Ile7Thr	missense variant	-	NC_000009.12:g.97983575T>C	gnomAD
rs866406709	p.Leu9Met	missense variant	-	NC_000009.12:g.97983580C>A	gnomAD
rs1443098778	p.Glu10Lys	missense variant	-	NC_000009.12:g.97983583G>A	TOPMed
rs1382043461	p.Glu10Val	missense variant	-	NC_000009.12:g.97983584A>T	gnomAD
rs1017983718	p.Thr15Ala	missense variant	-	NC_000009.12:g.97983598A>G	TOPMed,gnomAD
rs374378445	p.Thr15Ile	missense variant	-	NC_000009.12:g.97983599C>T	ESP,ExAC,TOPMed,gnomAD
rs866732118	p.Pro16Leu	missense variant	-	NC_000009.12:g.97983602C>T	gnomAD
rs866732118	p.Pro16Gln	missense variant	-	NC_000009.12:g.97983602C>A	gnomAD
rs1276585548	p.Ala17Glu	missense variant	-	NC_000009.12:g.97983605C>A	TOPMed
rs1234200164	p.Ala18Gly	missense variant	-	NC_000009.12:g.97983608C>G	gnomAD
rs1234200164	p.Ala18Asp	missense variant	-	NC_000009.12:g.97983608C>A	gnomAD
rs776354657	p.Arg20Gln	missense variant	-	NC_000009.12:g.97994635G>A	ExAC,gnomAD
COSM3432694	p.Arg20Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000009.12:g.97994634C>T	NCI-TCGA Cosmic
COSM752335	p.Ser29Ter	stop gained	Variant assessed as Somatic; HIGH impact.	NC_000009.12:g.97994662C>G	NCI-TCGA Cosmic
COSM1314305	p.Asn30Ile	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000009.12:g.97994665A>T	NCI-TCGA Cosmic
rs142118802	p.Lys33Asn	missense variant	-	NC_000009.12:g.97994675A>C	ESP,ExAC
rs376602943	p.Ile34Thr	missense variant	-	NC_000009.12:g.97994677T>C	ESP,TOPMed,gnomAD
rs1469384005	p.Ala39Thr	missense variant	-	NC_000009.12:g.97994691G>A	gnomAD
rs1358288838	p.Ala39Asp	missense variant	-	NC_000009.12:g.97994692C>A	gnomAD
rs1218929127	p.Glu45Asp	missense variant	-	NC_000009.12:g.97994711G>T	gnomAD
rs767568260	p.Leu47Pro	missense variant	-	NC_000009.12:g.97994716T>C	ExAC,gnomAD
rs973099581	p.Ser48Gly	missense variant	-	NC_000009.12:g.97994718A>G	TOPMed
rs756222170	p.Val52Ile	missense variant	-	NC_000009.12:g.97994730G>A	ExAC,gnomAD
COSM1464343	p.Leu60Arg	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000009.12:g.97994755T>G	NCI-TCGA Cosmic
NCI-TCGA novel	p.Leu60Ile	missense variant	-	NC_000009.12:g.97994754C>A	NCI-TCGA
COSM3835257	p.Lys62Met	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000009.12:g.97994761A>T	NCI-TCGA Cosmic
rs1473362999	p.Leu63Met	missense variant	-	NC_000009.12:g.97994763C>A	gnomAD
rs764181693	p.Pro64His	missense variant	-	NC_000009.12:g.97994767C>A	ExAC,gnomAD
COSM1103077	p.Lys68Gln	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000009.12:g.97994778A>C	NCI-TCGA Cosmic
rs138669342	p.Leu71Phe	missense variant	-	NC_000009.12:g.97998562C>T	ESP,ExAC,TOPMed,gnomAD
rs1311655242	p.Ser72Gly	missense variant	-	NC_000009.12:g.97998565A>G	gnomAD
NCI-TCGA novel	p.Gly78Glu	missense variant	-	NC_000009.12:g.97998584G>A	NCI-TCGA
rs991523817	p.Gly79Ser	missense variant	-	NC_000009.12:g.97998586G>A	gnomAD
rs1231206458	p.Gly79Val	missense variant	-	NC_000009.12:g.97998587G>T	gnomAD
rs1324561783	p.Leu80Met	missense variant	-	NC_000009.12:g.97998589C>A	gnomAD
rs1178261907	p.Ala84Val	missense variant	-	NC_000009.12:g.97998602C>T	gnomAD
rs753976201	p.Ala84Thr	missense variant	-	NC_000009.12:g.97998601G>A	ExAC,gnomAD
rs757567396	p.Glu85Gly	missense variant	-	NC_000009.12:g.97998605A>G	ExAC,gnomAD
rs765686344	p.Leu87Pro	missense variant	-	NC_000009.12:g.97998611T>C	ExAC,gnomAD
rs750761331	p.Pro88Leu	missense variant	-	NC_000009.12:g.97998614C>T	ExAC,gnomAD
rs1378945982	p.Asn89Tyr	missense variant	-	NC_000009.12:g.97998616A>T	gnomAD
rs1272322942	p.Thr91Ile	missense variant	-	NC_000009.12:g.97998623C>T	gnomAD
rs758841211	p.Thr91Ala	missense variant	-	NC_000009.12:g.97998622A>G	ExAC,gnomAD
rs1448780591	p.Asn98Ser	missense variant	-	NC_000009.12:g.97998644A>G	gnomAD
rs754411628	p.Lys101Asn	missense variant	-	NC_000009.12:g.97998654A>C	ExAC,gnomAD
rs1366853824	p.Asp102Val	missense variant	-	NC_000009.12:g.97998656A>T	gnomAD
NCI-TCGA novel	p.Asp102Ala	missense variant	-	NC_000009.12:g.97998656A>C	NCI-TCGA
rs1437197011	p.Ile103Thr	missense variant	-	NC_000009.12:g.97998659T>C	TOPMed,gnomAD
rs535530800	p.Ile103Met	missense variant	-	NC_000009.12:g.97998660C>G	1000Genomes,ExAC,TOPMed,gnomAD
rs1156729575	p.Ser104Arg	missense variant	-	NC_000009.12:g.97998663C>G	TOPMed
rs777366211	p.Lys110Glu	missense variant	-	NC_000009.12:g.98004964A>G	ExAC,gnomAD
rs1382025307	p.Glu113Gln	missense variant	-	NC_000009.12:g.98004973G>C	TOPMed
rs748979952	p.Ser117Ile	missense variant	-	NC_000009.12:g.98004986G>T	ExAC,TOPMed,gnomAD
rs748979952	p.Ser117Asn	missense variant	-	NC_000009.12:g.98004986G>A	ExAC,TOPMed,gnomAD
rs1476195765	p.Leu120Phe	missense variant	-	NC_000009.12:g.98004994C>T	TOPMed,gnomAD
rs1476195765	p.Leu120Val	missense variant	-	NC_000009.12:g.98004994C>G	TOPMed,gnomAD
rs1412787627	p.Asn122Ile	missense variant	-	NC_000009.12:g.98005001A>T	gnomAD
NCI-TCGA novel	p.Glu124Val	missense variant	-	NC_000009.12:g.98005007A>T	NCI-TCGA
rs377406514	p.Leu128Val	missense variant	-	NC_000009.12:g.98005018C>G	ESP,ExAC,gnomAD
rs182096718	p.Asp130Ala	missense variant	-	NC_000009.12:g.98005025A>C	1000Genomes,ESP,ExAC,TOPMed,gnomAD
COSM5131905	p.Asp130Gly	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000009.12:g.98005025A>G	NCI-TCGA Cosmic
rs771977254	p.Glu133Gln	missense variant	-	NC_000009.12:g.98005033G>C	ExAC,gnomAD
rs775300881	p.Ser134Arg	missense variant	-	NC_000009.12:g.98005038T>G	ExAC,gnomAD
rs1431749321	p.Val135Ile	missense variant	-	NC_000009.12:g.98005039G>A	TOPMed,gnomAD
rs1302544606	p.Lys137Arg	missense variant	-	NC_000009.12:g.98005046A>G	gnomAD
rs1302544606	p.Lys137Thr	missense variant	-	NC_000009.12:g.98005046A>C	gnomAD
rs761932651	p.Leu138His	missense variant	-	NC_000009.12:g.98005049T>A	ExAC,gnomAD
COSM1103079	p.Leu139Pro	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000009.12:g.98005052T>C	NCI-TCGA Cosmic
rs1418539448	p.Gln141Arg	missense variant	-	NC_000009.12:g.98005058A>G	TOPMed
rs770020996	p.Leu142Phe	missense variant	-	NC_000009.12:g.98005060C>T	ExAC,gnomAD
rs374883415	p.Thr143Ile	missense variant	-	NC_000009.12:g.98005064C>T	ESP,ExAC,gnomAD
COSM3902467	p.Tyr144Cys	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000009.12:g.98005067A>G	NCI-TCGA Cosmic
rs1283264647	p.Gly147Ser	missense variant	-	NC_000009.12:g.98005075G>A	gnomAD
rs1448292635	p.Tyr148Phe	missense variant	-	NC_000009.12:g.98005079A>T	gnomAD
rs1046534844	p.Asp149Glu	missense variant	-	NC_000009.12:g.98005083C>G	TOPMed
rs149318680	p.Arg150Gln	missense variant	-	NC_000009.12:g.98005085G>A	ESP,ExAC,TOPMed,gnomAD
COSM1103080	p.Gln153Leu	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000009.12:g.98005094A>T	NCI-TCGA Cosmic
rs759833673	p.Pro156Ala	missense variant	-	NC_000009.12:g.98005102C>G	ExAC,gnomAD
rs759833673	p.Pro156Ser	missense variant	-	NC_000009.12:g.98005102C>T	ExAC,gnomAD
rs1156850890	p.Ala160Val	missense variant	-	NC_000009.12:g.98005115C>T	gnomAD
rs201273635	p.Ala160Thr	missense variant	-	NC_000009.12:g.98005114G>A	1000Genomes
rs1251083232	p.Glu161Lys	missense variant	-	NC_000009.12:g.98005117G>A	TOPMed
rs1325404711	p.Val162Glu	missense variant	-	NC_000009.12:g.98005121T>A	gnomAD
rs1401408342	p.Asp163Gly	missense variant	-	NC_000009.12:g.98005124A>G	gnomAD
rs753476000	p.Val165Met	missense variant	-	NC_000009.12:g.98005129G>A	ExAC,gnomAD
rs756969084	p.Asp166Gly	missense variant	-	NC_000009.12:g.98005133A>G	ExAC,gnomAD
rs1232087697	p.Glu167Asp	missense variant	-	NC_000009.12:g.98005137A>C	TOPMed
rs745616807	p.Glu170Asp	missense variant	-	NC_000009.12:g.98005146G>C	ExAC,TOPMed,gnomAD
rs1445206658	p.Asp171His	missense variant	-	NC_000009.12:g.98005147G>C	gnomAD
rs1481491470	p.Gly174Arg	missense variant	-	NC_000009.12:g.98011273G>A	gnomAD
rs1200375028	p.Gly174Val	missense variant	-	NC_000009.12:g.98011274G>T	gnomAD
NCI-TCGA novel	p.Gly174LysPheSerTerUnkUnk	frameshift	-	NC_000009.12:g.98005153_98005154insAA	NCI-TCGA
rs1423224178	p.Glu175Asp	missense variant	-	NC_000009.12:g.98011278A>T	gnomAD
rs1464349905	p.Asp176Gly	missense variant	-	NC_000009.12:g.98011280A>G	gnomAD
rs1316585223	p.Glu177Val	missense variant	-	NC_000009.12:g.98011283A>T	TOPMed,gnomAD
rs1340831822	p.Asp179Gly	missense variant	-	NC_000009.12:g.98011289A>G	TOPMed
rs1023323281	p.Asp179Asn	missense variant	-	NC_000009.12:g.98011288G>A	TOPMed
rs1397753391	p.Glu180Lys	missense variant	-	NC_000009.12:g.98011291G>A	gnomAD
rs1363146642	p.Asp182Asn	missense variant	-	NC_000009.12:g.98011297G>A	gnomAD
rs1406283932	p.Asp182Glu	missense variant	-	NC_000009.12:g.98011299T>G	TOPMed,gnomAD
rs1283480300	p.Asp184Asn	missense variant	-	NC_000009.12:g.98011303G>A	gnomAD
rs1339906176	p.Glu189Ala	missense variant	-	NC_000009.12:g.98011319A>C	gnomAD
rs1223355183	p.Asp191Val	missense variant	-	NC_000009.12:g.98011325A>T	gnomAD
rs781295072	p.Glu192Asp	missense variant	-	NC_000009.12:g.98011329A>T	ExAC,gnomAD
rs554324727	p.Glu193Gly	missense variant	-	NC_000009.12:g.98011331A>G	1000Genomes,ExAC,gnomAD
rs1000014447	p.Glu193Asp	missense variant	-	NC_000009.12:g.98011332A>T	TOPMed
rs770948925	p.Asp194Glu	missense variant	-	NC_000009.12:g.98011335T>A	ExAC
rs1472704292	p.Glu196Asp	missense variant	-	NC_000009.12:g.98011341A>T	gnomAD
rs1206430307	p.Asp197Val	missense variant	-	NC_000009.12:g.98011343A>T	gnomAD
rs1474420460	p.Asp199Val	missense variant	-	NC_000009.12:g.98011349A>T	TOPMed
NCI-TCGA novel	p.Val200Ile	missense variant	-	NC_000009.12:g.98011351G>A	NCI-TCGA
rs774602963	p.Gly202Arg	missense variant	-	NC_000009.12:g.98011357G>A	ExAC,gnomAD
rs746127276	p.Asp203His	missense variant	-	NC_000009.12:g.98011360G>C	ExAC,TOPMed,gnomAD
NCI-TCGA novel	p.Glu204AlaGlyIleLysTer	stop gained	-	NC_000009.12:g.98011363_98011364insCAGGAATAAAAT	NCI-TCGA
rs147068709	p.Asp205Glu	missense variant	-	NC_000009.12:g.98011368C>A	1000Genomes,ESP,ExAC,TOPMed,gnomAD
rs1359422504	p.Asp205Asn	missense variant	-	NC_000009.12:g.98011366G>A	gnomAD
rs1319941915	p.Asp206Asn	missense variant	-	NC_000009.12:g.98011369G>A	TOPMed,gnomAD
rs1319941915	p.Asp206Asn	missense variant	-	NC_000009.12:g.98011369G>A	NCI-TCGA Cosmic
rs761031783	p.Asp207Tyr	missense variant	-	NC_000009.12:g.98011372G>T	ExAC,gnomAD
rs761031783	p.Asp207Asn	missense variant	-	NC_000009.12:g.98011372G>A	ExAC,gnomAD
rs761031783	p.Asp207Asn	missense variant	-	NC_000009.12:g.98011372G>A	NCI-TCGA,NCI-TCGA Cosmic
COSM5130751	p.Glu208Gly	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000009.12:g.98011376A>G	NCI-TCGA Cosmic
rs761343165	p.Val209Gly	missense variant	-	NC_000009.12:g.98011379T>G	ExAC,gnomAD
rs370631624	p.Val209Ile	missense variant	-	NC_000009.12:g.98011378G>A	ESP,ExAC,gnomAD
rs1330930663	p.Glu211Gln	missense variant	-	NC_000009.12:g.98011384G>C	TOPMed
rs1330930663	p.Glu211Ter	stop gained	-	NC_000009.12:g.98011384G>T	TOPMed
NCI-TCGA novel	p.Glu211Lys	missense variant	-	NC_000009.12:g.98011384G>A	NCI-TCGA
rs1384813255	p.Glu215Gln	missense variant	-	NC_000009.12:g.98012427G>C	gnomAD
NCI-TCGA novel	p.Glu215Lys	missense variant	-	NC_000009.12:g.98012427G>A	NCI-TCGA
rs769036871	p.Phe216Cys	missense variant	-	NC_000009.12:g.98012431T>G	ExAC,gnomAD
rs777088502	p.Gly217Ala	missense variant	-	NC_000009.12:g.98012434G>C	ExAC,gnomAD
rs769329548	p.Asp219Glu	missense variant	-	NC_000009.12:g.98012441T>A	ExAC
rs762271758	p.Asp219Gly	missense variant	-	NC_000009.12:g.98012440A>G	ExAC,gnomAD
rs1344592227	p.Asp222Gly	missense variant	-	NC_000009.12:g.98012449A>G	TOPMed,gnomAD
rs1202090461	p.Asp222Glu	missense variant	-	NC_000009.12:g.98012450T>A	gnomAD
rs1344592227	p.Asp222Val	missense variant	-	NC_000009.12:g.98012449A>T	TOPMed,gnomAD
rs1245351372	p.Asp224Glu	missense variant	-	NC_000009.12:g.98012456T>A	gnomAD
rs772534076	p.Glu225Lys	missense variant	-	NC_000009.12:g.98012457G>A	ExAC,gnomAD
rs3900080	p.Glu225Asp	missense variant	-	NC_000009.12:g.98012459G>C	ExAC,gnomAD
rs769811711	p.Asp228Gly	missense variant	-	NC_000009.12:g.98012467A>G	ExAC,gnomAD
rs1247883639	p.Asp228Asn	missense variant	-	NC_000009.12:g.98012466G>A	TOPMed
rs987139	p.Glu230Lys	missense variant	-	NC_000009.12:g.98012472G>A	TOPMed
rs1196801497	p.Glu230Asp	missense variant	-	NC_000009.12:g.98015365G>T	gnomAD
rs1431018280	p.Glu231Lys	missense variant	-	NC_000009.12:g.98015366G>A	gnomAD
rs1335613382	p.Glu231Asp	missense variant	-	NC_000009.12:g.98015368G>C	TOPMed
COSM4832286	p.Glu233Gln	missense variant	Variant assessed as Somatic; MODERATE impact.	NC_000009.12:g.98015372G>C	NCI-TCGA Cosmic
rs796129328	p.Gly234Ser	missense variant	-	NC_000009.12:g.98015375G>A	gnomAD
rs796924529	p.Gly235Arg	missense variant	-	NC_000009.12:g.98015378G>A	gnomAD
NCI-TCGA novel	p.Gly237Cys	missense variant	-	NC_000009.12:g.98015384G>T	NCI-TCGA
rs1389054833	p.Arg242Lys	missense variant	-	NC_000009.12:g.98015400G>A	TOPMed
rs1169708902	p.Thr244Arg	missense variant	-	NC_000009.12:g.98015406C>G	gnomAD
rs1352619278	p.Asp245His	missense variant	-	NC_000009.12:g.98015408G>C	gnomAD
NCI-TCGA novel	p.Asp245Tyr	missense variant	-	NC_000009.12:g.98015408G>T	NCI-TCGA
rs1367645400	p.Gly248Arg	missense variant	-	NC_000009.12:g.98015417G>A	TOPMed
rs1463455065	p.Glu249Asp	missense variant	-	NC_000009.12:g.98015422A>T	gnomAD
rs76167314	p.Asp250Asn	missense variant	-	NC_000009.12:g.98015423G>A	gnomAD
rs112073824	p.Asp251Glu	missense variant	-	NC_000009.12:g.98015428T>G	TOPMed,gnomAD
rs112073824	p.Asp251Glu	missense variant	-	NC_000009.12:g.98015428T>A	TOPMed,gnomAD
rs112073824	p.Asp251Glu	missense variant	-	NC_000009.12:g.98015428T>G	NCI-TCGA

Disease or phenotype associated information

Disease ID	Disease Name	Disease Type	Source
C0001430	Adenoma	group	BEFREE
C0003873	Rheumatoid Arthritis	disease	BEFREE
C0004096	Asthma	disease	BEFREE
C0004364	Autoimmune Diseases	group	BEFREE
C0006142	Malignant neoplasm of breast	disease	BEFREE
C0007137	Squamous cell carcinoma	disease	BEFREE
C0009319	Colitis	disease	BEFREE
C0009402	Colorectal Carcinoma	disease	BEFREE
C0009447	Common Variable Immunodeficiency	disease	BEFREE
C0010054	Coronary Arteriosclerosis	disease	BEFREE
C0010068	Coronary heart disease	disease	BEFREE
C0011615	Dermatitis, Atopic	disease	BEFREE
C0013595	Eczema	disease	BEFREE
C0014772	Red Blood Cell Count measurement	phenotype	GWASCAT
C0017636	Glioblastoma	disease	BEFREE
C0017638	Glioma	disease	BEFREE
C0019829	Hodgkin Disease	disease	BEFREE
C0023418	leukemia	disease	BEFREE
C0023434	Chronic Lymphocytic Leukemia	disease	BEFREE
C0024141	Lupus Erythematosus, Systemic	disease	BEFREE
C0024143	Lupus Nephritis	disease	BEFREE
C0024419	Waldenstrom Macroglobulinemia	disease	BEFREE
C0024623	Malignant neoplasm of stomach	disease	BEFREE
C0026470	Monoclonal Gammopathy of Undetermined Significance	disease	BEFREE
C0026764	Multiple Myeloma	disease	BEFREE
C0026769	Multiple Sclerosis	disease	BEFREE
C0027051	Myocardial Infarction	disease	BEFREE
C0027627	Neoplasm Metastasis	phenotype	BEFREE
C0029408	Degenerative polyarthritis	disease	BEFREE
C0029453	Osteopenia	disease	BEFREE
C0031099	Periodontitis	disease	BEFREE
C0033860	Psoriasis	disease	BEFREE
C0035435	Rheumatism	disease	BEFREE
C0036508	Seborrheic dermatitis	disease	BEFREE
C0079731	B-Cell Lymphomas	group	BEFREE
C0178874	Tumor Progression	phenotype	BEFREE
C0206161	Reticulocyte count (procedure)	phenotype	GWASCAT
C0242584	Autoimmune thrombocytopenia	disease	BEFREE
C0272286	Thrombocytopenia due to platelet alloimmunization	disease	BEFREE
C0280100	Solid Neoplasm	phenotype	BEFREE
C0369183	Erythrocyte Mean Corpuscular Hemoglobin Test	phenotype	GWASCAT
C0376545	Hematologic Neoplasms	group	BEFREE
C0398650	Immune thrombocytopenic purpura	disease	BEFREE
C0555198	Malignant Glioma	disease	BEFREE
C0596263	Carcinogenesis	phenotype	BEFREE
C0598766	Leukemogenesis	disease	BEFREE
C0678222	Breast Carcinoma	disease	BEFREE
C0699791	Stomach Carcinoma	disease	BEFREE
C0948780	Rhinosinusitis	disease	BEFREE
C1261502	Finding of Mean Corpuscular Hemoglobin	phenotype	GWASCAT
C1319315	Adenocarcinoma of large intestine	disease	BEFREE
C1527249	Colorectal Cancer	disease	BEFREE
C1840264	IMMUNE SUPPRESSION	phenotype	BEFREE
C1956346	Coronary Artery Disease	disease	BEFREE
C2936664	Acquired Hypogammaglobulinemia	disease	BEFREE
C3495801	Granulomatosis with polyangiitis	disease	BEFREE
C4054543	Membranous Lupus Nephritis	disease	BEFREE

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO ID	GO Term	Evidence
GO:0005515	protein binding	IPI
GO:0042393	histone binding	IDA
GO:0042393	histone binding	IBA
GO:0070063	RNA polymerase binding	IDA

GO:Biological Process

GO ID	GO Term	Evidence
GO:0001944	vasculature development	IEA
GO:0006334	nucleosome assembly	IDA
GO:0006919	activation of cysteine-type endopeptidase activity involved in apoptotic process	IMP
GO:0021591	ventricular system development	IEA
GO:0042981	regulation of apoptotic process	IBA
GO:0045596	negative regulation of cell differentiation	IDA
GO:0046827	positive regulation of protein export from nucleus	IMP
GO:0048839	inner ear development	IEA
GO:0060021	roof of mouth development	IEA

GO:Cellular Component

GO ID	GO Term	Evidence
GO:0005634	nucleus	HDA
GO:0005634	nucleus	IDA
GO:0005654	nucleoplasm	IDA
GO:0005737	cytoplasm	IDA
GO:0070062	extracellular exosome	HDA
GO:0005730	nucleolus	IDA

Reactome Pathway

Reactome ID	Reactome Term	Evidence

Drugs and compounds information

ID	Drug Name	Action	PubMed
C016403	2,4-dinitrotoluene	2,4-dinitrotoluene affects the expression of ANP32B mRNA	21346803
C000595015	6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine	6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine results in decreased expression of ANP32B mRNA	28073004
D015123	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of ANP32B mRNA	19150397; 20382639;
C496492	abrine	abrine results in decreased expression of ANP32B mRNA	31054353
D000082	Acetaminophen	Acetaminophen affects the expression of ANP32B mRNA	17562736
C100057	ametryne	ametryne results in decreased expression of ANP32B protein	29427468
D000616	Aminoglutethimide	Aminoglutethimide results in decreased expression of ANP32B protein	26102013
D000643	Ammonium Chloride	Ammonium Chloride affects the expression of ANP32B mRNA	16483693
D000077237	Arsenic Trioxide	Arsenic Trioxide results in increased expression of ANP32B mRNA	20458559
D001564	Benzo(a)pyrene	AHR protein inhibits the reaction [Benzo(a)pyrene results in increased expression of ANP32B mRNA]	15034205
D001564	Benzo(a)pyrene	Benzo(a)pyrene results in increased expression of ANP32B mRNA	15034205
C006780	bisphenol A	bisphenol A affects the expression of ANP32B mRNA	21786754
C006780	bisphenol A	bisphenol A affects the expression of ANP32B mRNA	30903817
C006780	bisphenol A	bisphenol A affects the expression of ANP32B mRNA	25181051
D002066	Busulfan	[Clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased cleavage of ANP32B protein	20933509
C018475	butyraldehyde	butyraldehyde results in decreased expression of ANP32B mRNA	26079696
D019256	Cadmium Chloride	Cadmium Chloride results in increased methylation of ANP32B promoter	22457795
C010063	carbonyl sulfide	carbonyl sulfide results in increased expression of ANP32B mRNA	19395590
D020111	Chlorodiphenyl (54% Chlorine)	Chlorodiphenyl (54% Chlorine) results in decreased expression of ANP32B mRNA	23650126
C100187	chloropicrin	chloropicrin results in decreased expression of ANP32B mRNA	26352163
D002794	Choline	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ANP32B gene	20938992
C074702	chromium hexavalent ion	chromium hexavalent ion affects the expression of ANP32B mRNA	28472532
D000077866	Clofarabine	[Clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased cleavage of ANP32B protein	20933509
D002995	Clofibric Acid	[Diethylnitrosamine co-treated with Clofibric Acid] affects the expression of ANP32B mRNA	17602206
D019327	Copper Sulfate	Copper Sulfate results in decreased expression of ANP32B mRNA	19020976
D003471	Cuprizone	Cuprizone results in increased expression of ANP32B mRNA	27523638
D016572	Cyclosporine	Cyclosporine results in increased expression of ANP32B mRNA	20106945
D003993	Dibutyl Phthalate	Dibutyl Phthalate results in decreased expression of ANP32B mRNA	21266533
D004041	Dietary Fats	Dietary Fats results in increased expression of ANP32B mRNA	25016146
D004052	Diethylnitrosamine	[Diethylnitrosamine co-treated with Clofibric Acid] affects the expression of ANP32B mRNA	17602206
D004317	Doxorubicin	Doxorubicin results in decreased expression of ANP32B mRNA	29803840
D004791	Enzyme Inhibitors	[Enzyme Inhibitors results in decreased activity of OGA protein] which results in increased O-linked glycosylation of ANP32B protein	23301498
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of ANP32B mRNA	17942748
D004997	Ethinyl Estradiol	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ANP32B mRNA	17942748
D004997	Ethinyl Estradiol	Ethinyl Estradiol results in increased expression of ANP32B mRNA	23129252
C024352	fludarabine	[Clofarabine co-treated with fludarabine co-treated with Busulfan] results in increased cleavage of ANP32B protein	20933509
D005485	Flutamide	Flutamide results in increased expression of ANP32B mRNA	24136188
D005492	Folic Acid	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ANP32B gene	20938992
D005839	Gentamicins	Gentamicins results in increased expression of ANP32B mRNA	22061828
C000593030	GSK-J4	GSK-J4 results in increased expression of ANP32B mRNA	29301935
D008715	Methionine	[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ANP32B gene	20938992
D008777	Methyltestosterone	Methyltestosterone results in increased expression of ANP32B mRNA	29458080
D037742	Nanotubes, Carbon	Nanotubes, Carbon analog results in increased expression of ANP32B mRNA	25554681
C051752	nefazodone	nefazodone results in increased expression of ANP32B mRNA	24136188
D009534	Niclosamide	Niclosamide results in decreased expression of ANP32B mRNA	31398420
D000077150	Oxaliplatin	[Oxaliplatin co-treated with Topotecan] results in decreased expression of ANP32B mRNA	25729387
C005290	oxybenzone	oxybenzone results in increased expression of ANP32B mRNA	22721600
C006253	pirinixic acid	pirinixic acid results in increased expression of ANP32B mRNA	23811191
C005556	propionaldehyde	propionaldehyde results in decreased expression of ANP32B mRNA	26079696
C513635	S-2-pentyl-4-pentynoic hydroxamic acid	S-2-pentyl-4-pentynoic hydroxamic acid results in decreased expression of ANP32B mRNA	21427059
D012643	Selenium	[Selenium co-treated with Vitamin E] results in decreased expression of ANP32B mRNA	19244175
D012999	Soman	Soman results in increased expression of ANP32B mRNA	19281266
D053260	Soot	Soot results in increased expression of ANP32B mRNA	26551751
D013605	T-2 Toxin	T-2 Toxin affects the expression of ANP32B protein	26141394
D013749	Tetrachlorodibenzodioxin	AHR protein inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of ANP32B mRNA]	15034205
D013749	Tetrachlorodibenzodioxin	[Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of ANP32B mRNA	17942748
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin results in increased expression of ANP32B mRNA	15034205
D013849	Thimerosal	Thimerosal results in decreased expression of ANP32B mRNA	27188386
D019772	Topotecan	[Oxaliplatin co-treated with Topotecan] results in decreased expression of ANP32B mRNA	25729387
D014212	Tretinoin	Tretinoin results in increased expression of ANP32B protein	11331971
C012589	trichostatin A	trichostatin A results in decreased expression of ANP32B mRNA	15901671
C012589	trichostatin A	trichostatin A affects the expression of ANP32B mRNA	28542535
C015559	trimellitic anhydride	trimellitic anhydride results in increased expression of ANP32B mRNA	19042947
D000077288	Troglitazone	Troglitazone results in decreased expression of ANP32B mRNA	28973697
D014635	Valproic Acid	Valproic Acid results in decreased expression of ANP32B mRNA	15901671
D014635	Valproic Acid	Valproic Acid affects the expression of ANP32B mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in decreased expression of ANP32B mRNA	23179753; 27188386; 28001369;
D014635	Valproic Acid	Valproic Acid results in increased methylation of ANP32B gene	29154799
D014635	Valproic Acid	Valproic Acid results in decreased expression of ANP32B mRNA	20546886; 21427059;
D014810	Vitamin E	[Selenium co-treated with Vitamin E] results in decreased expression of ANP32B mRNA	19244175
D014810	Vitamin E	Vitamin E results in decreased expression of ANP32B mRNA	19244175
D024483	Vitamin K 3	Vitamin K 3 affects the expression of ANP32B mRNA	20044591
D000077337	Vorinostat	Vorinostat results in decreased expression of ANP32B mRNA	27188386

Functional annotations

Keywords

Keyword ID	Keyword Term
KW-0002	3D-structure
KW-0007	Acetylation
KW-0025	Alternative splicing
KW-0143	Chaperone
KW-0963	Cytoplasm
KW-0433	Leucine-rich repeat
KW-0539	Nucleus
KW-0597	Phosphoprotein
KW-1185	Reference proteome
KW-0677	Repeat

Interpro

InterPro ID	InterPro Term
IPR001611	Leu-rich_rpt
IPR032675	LRR_dom_sf
IPR003603	U2A'_phosphoprotein32A_C

PROSITE

PROSITE ID	PROSITE Term
PS51450	LRR

Pfam

Pfam ID	Pfam Term

Gene: ANP32B

Basic information

Gene expression information

Gene expression in different tissues (GTEx V7)

Gene expression in different tissues (ENCODE)

Protein structural annotations

3D structure in PDB database

Protein disorder information

Orthologous information

Other genetic variants/mutations

Disease or phenotype associated information

Gene Ontology (GO)/biological pathways

GO:Molecular Function

GO:Biological Process

GO:Cellular Component

Reactome Pathway

Drugs and compounds information

Functional annotations

Keywords

Interpro

PROSITE

Pfam

Protein-protein interaction

Protein-miRNA interaction